BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11325667)

  • 1. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
    Fishbane S; Wagner J
    Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
    Fishbane S; Kowalski EA
    Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 14. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to iron sucrose in dialysis patients sensitive to iron dextran.
    Gupta A; Khaira A; Dogra M; Agarwal SK
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):744-5; author reply 745. PubMed ID: 20587886
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran.
    Bastani B; Rahman S; Gellens M
    ASAIO J; 2002; 48(4):404-6. PubMed ID: 12141472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
    Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
    Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 20. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.